We recommend that emergency physicians ask patients about trip-killers if psychedelic drug use is suspected. This conversation should occur promptly on arrival to hospital, and before any benzodiazepines or antipsychotics are prescribed

The following reviews the current research for clinical pharmacotherapies, as well as MDMA-integrative psychotherapy as they pertain to PTSD and AUD in isolation and co-occurrence. Future directions for the role of psychedelic-integrative therapy for the treatment of this comorbidity are discussed.

Evidence suggests that low-dose oral ketamine is clinically effective in treating pain. This may also be due to the actions of norketamine and therefore, its relevance to the mental health context is explored in this narrative review.

Seven days later, TNF-α concentrations returned to baseline, while IL-6 and CRP concentrations were persistently reduced in the psilocybin group ... Additionally, the more of a reduction in IL-6 and CRP seven days after psilocybin, the more persisting positive mood and social effects participants reported.

Proposed MAPS research projects for 2024 include MDMA-assisted Couples Therapy, Peace Building & Conflict Resolution, Marijuana for PTSD, and Psychedelics & the Legal System,

The results suggest that naturalistic use of psychedelics may be linked to reduced reactivity to emotionally negative stimuli at the early and automatic processing stages.

Findings of the study showed safety (no treatment-related serious adverse events or suicidality) with psilocybin and suggested efficacy, with a significant reduction in depression severity scores from baseline to posttreatment. Further investigation is warranted.

Treatment of psychiatric disorders with psychedelic substances represents one of the most promising current treatment approaches in psychiatry.

The FDA has 60 days to determine whether the NDA will be accepted for review and whether it will be a priority or standard review (six months or ten months, respectively).

Adopting group therapy protocols where feasible would significantly reduce the cost of psychedelic-assisted therapies.

We suggest that classic psychedelic-assisted therapies can be integrated into most mainstream evidence-based SUD treatments that are currently used in clinical settings, indicating broad compatibility of classic psychedelics with contemporary SUD treatment paradigms.

These findings suggest that an acute low dose of LSD (26 µg) elicits more pronounced positive mood and stimulant-like effects, as well as stronger altered states of consciousness in individuals with depressive symptoms, compared to non-depressed individuals.

The findings in this open-label nonrandomized controlled trial suggest efficacy and safety of psilocybin with psychotherapy in BDII depression and supports further study of psychedelics in this population.

Tim Ferriss talks with Dr Willoughby Britton about her ground-breaking (and often unpopular) research highlighting potential dangers and worrying frequency of adverse effects associated with meditation practices (and similarly psychedelics).